pocketful logo
Godavari Drugs Ltd logo

Godavari Drugs Ltd

NSE: BSE: 530317

88.67

(-2.23)%

Fri, 06 Feb 2026, 01:38 am

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    66.77

  • Net Profit

    4.38

  • P/B

    1.52

  • Sector P/E

    39.83

  • P/E

    15.03

  • EV/EBITDA

    9.98

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    22.44

  • ROCE (Industry)

    20.01

  • RONW (Industry)

    16.77

  • ROE

    10.64

  • ROCE

    10.06

  • Debt/Equity

    1.48

  • EPS (TTM)

    5.78

  • Dividend Yield

    0

  • Book Value

    57.56

  • Interest Cover

    2.19

Analysis

all

thumbs up icon

Pros

  • Godavari Drugs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Godavari Drugs is profitable, therefore cash runway is not a concern.
  • Godavari Drugs is profitable, therefore cash runway is not a concern.
  • Debt is covered by short term assets, assets are 2.3x debt.
  • Godavari Drugs's cash and other short term assets cover its long term commitments.
thumbs up icon

Cons

  • Unable to evaluate Godavari Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Godavari Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Debt is not well covered by operating cash flow (15.1%, less than 20% of total debt).
  • The level of debt compared to net worth has increased over the past 5 years (31.5% vs 129.5% today).
  • Interest payments on debt are not well covered by earnings (EBIT is 2x annual interest expense, ideally 3x coverage).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters52.6152.6152.6352.6352.63
FII00000
DII0.500.500.500.500.50
Public46.8946.8946.8746.8746.87
Government00000

Read More

Technical Analysis

RSI

51.31

MACD

1.67

50 DMA

82.15

200 DMA

86.57

Support and Resistance

TypeR1R2R3PPS1S2S3
Classic155.22121.87104.9888.5271.6355.1721.82
Fibonacci121.87109.13101.2688.5275.7867.9155.17
Camarilla97.2794.2191.1688.5285.0481.9978.93

Pivots Level: Classic

R3

+66.70

155.22

R2

+33.35

121.87

R1

+16.47

104.98

88.52
88.52
Pivot Point
LTP: 88.67

S1

-16.88

71.63

S2

-33.35

55.17

S3

-66.70

21.82

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    89.36

  • 20-EMA

    88.44

  • 30-EMA

    87.10

  • 50-EMA

    85.29

  • 100-EMA

    84.54

  • 200-EMA

    87.42

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
21 Jan 2026egm
14 Nov 2025board-meetingsQuarterly Results
04 Aug 2025agm
30 May 2024agm
21 Jul 2023agm
25 Apr 2022agm
23 Jul 2021agm

Read More

Peer Comparison

Godavari Drugs Ltd logo

Godavari Drugs Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

About Godavari Drugs Ltd

Godavari Drugs engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and its intermediates through its manufacturing facility at Nanded, Maharashtra, India.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1987

Headquarters

CEO

Ghanshyam Jaju

Employees

Contact

Website icon

Website

http://www.godavaridrugs.com

Email icon

Email

info@godavaridrugs.com

Phone icon

Phone

91-40-27849700/27844557

Location icon

Location

Mayfair 1-8-303-34, Sardar Patel Road, Secunderabad, Andhra Pradesh, 500003

Read More

godavari drugs ltd History

YearHistory
1987
  • GODAVARI DRUGS LIMITED was incorporated as a private limited company on December 2.
1988
  • The company set up a project to manufacture 180 TPA of SULPHAMETHOXAZOLE.
1989
  • The project to manufacture SULPHAMETHOXAZOLE was fully commissioned on July 3.
1992
  • The company was converted into a public limited company on September 25.
2012
  • The Board appointed Mr. Mohit Jaju as an Additional Director effective from May 10.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
No Result Found

Read More

godavari drugs ltd. News

Godavari Drugs Board Approves Preferential Issue

Godavari Drugs Limited board approves preferential issue of 23.60 lakh convertible warrants and 25.97 lakh equity shares at ₹89 each to promoters and non-promoters, subject to shareholder approval in EGM scheduled for February 12, 2026.

15 Jan 2026

co actions results

Godavari Drugs clarifies share price movement

Godavari Drugs Limited responds to BSE inquiry on share price volatility, stating no unpublished price sensitive information exists and attributing movement to market-driven demand-supply factors.

08 Jan 2026

stocks

Godavari Drugs Reports Mixed Q2 Performance with Revenue Growth but Margin Pressure

Godavari Drugs Limited reported revenue from operations of Rs 2,664.04 lakhs for the quarter ended September 30, 2025, up from Rs 2,608.79 lakhs in the same quarter last year, with net profit rising to Rs 100.07 lakhs from Rs 108.86 lakhs. The company's half-year revenue reached Rs 5,046.07 lakhs compared to Rs 5,829.54 lakhs in the previous year, while net profit for the six-month period stood at Rs 204.13 lakhs versus Rs 271.94 lakhs last year.

14 Nov 2025

earnings

Godavari Drugs Reports Q1 Results, Doubles Authorized Share Capital to ₹20 Crore

Godavari Drugs Limited reported unaudited financial results for the quarter ended June 30, 2025. The company posted revenue from operations of ₹2,381.13 lakhs compared to ₹3,220.75 lakhs in the same quarter last year. Net profit for the quarter was ₹104.06 lakhs versus ₹153.08 lakhs in the corresponding period last year. Earnings per share stood at ₹1.38 compared to ₹2.17 in the previous year quarter. The Board approved increasing the company's authorized share capital from ₹10 crore to ₹20 crore by creating an additional 1 crore equity shares of ₹10 each, subject to shareholder approval. The company also rescheduled its 37th Annual General Meeting from August 28, 2025 to September 27, 2025.

13 Aug 2025

earnings

Showing 14 of 4
Rows per page:

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800